Literature DB >> 8617884

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.

J Zabner1, B W Ramsey, D P Meeker, M L Aitken, R P Balfour, R L Gibson, J Launspach, R A Moscicki, S M Richards, T A Standaert.   

Abstract

Cystic fibrosis (CF) is a common autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator gene. Recombinant adenoviruses have shown promise as vectors for transfer of CF transmembrane conductance regulator cDNA to airway epithelia and correction of the Cl- transport defect. However, because adenovirus-mediated gene transfer is transient, use of adenovirus as a vector for treatment of CF would require repeated administration. Therefore, we evaluated repeat administration of an adenovirus vector to the nasal epithelium of patients with CF with five escalating doses of up to 10(10) infectious units. There were no detectable adverse affects. All subjects were initially seropositive but developed additional humoral immune responses. The vector partially corrected the defect in airway epithelial Cl- transport in some subjects, although there was variability between subjects and there was less correction with subsequent administration, perhaps because the immune response limited gene transfer. Future work must focus on vectors with increased efficiency and with the ability to evade host defenses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617884      PMCID: PMC507211          DOI: 10.1172/JCI118573

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus.

Authors:  M J Welsh; J Zabner; S M Graham; A E Smith; R Moscicki; S Wadsworth
Journal:  Hum Gene Ther       Date:  1995-02       Impact factor: 5.695

2.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.

Authors:  R G Crystal; N G McElvaney; M A Rosenfeld; C S Chu; A Mastrangeli; J G Hay; S L Brody; H A Jaffe; N T Eissa; C Danel
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

3.  IL-6 release and airway administration of human CFR cDNA adenovirus vector.

Authors:  N G McElvaney; R G Crystal
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

4.  Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.

Authors:  J G Hay; N G McElvaney; J Herena; R G Crystal
Journal:  Hum Gene Ther       Date:  1995-11       Impact factor: 5.695

5.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.

Authors:  M R Knowles; K W Hohneker; Z Zhou; J C Olsen; T L Noah; P C Hu; M W Leigh; J F Engelhardt; L J Edwards; K R Jones
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

6.  In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung.

Authors:  S Yei; N Mittereder; S Wert; J A Whitsett; R W Wilmott; B C Trapnell
Journal:  Hum Gene Ther       Date:  1994-06       Impact factor: 5.695

7.  In vivo adenovirus-mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium: efficacy, toxicity and safety.

Authors:  A Bout; J L Imler; H Schultz; M Perricaudet; C Zurcher; P Herbrink; D Valerio; A Pavirani
Journal:  Gene Ther       Date:  1994-11       Impact factor: 5.250

8.  Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.

Authors:  S Yei; N Mittereder; K Tang; C O'Sullivan; B C Trapnell
Journal:  Gene Ther       Date:  1994-05       Impact factor: 5.250

9.  Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells.

Authors:  L G Johnson; S E Boyles; J Wilson; R C Boucher
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

10.  Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans.

Authors:  B R Grubb; R J Pickles; H Ye; J R Yankaskas; R N Vick; J F Engelhardt; J M Wilson; L G Johnson; R C Boucher
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

View more
  56 in total

Review 1.  Status of gene therapy for cystic fibrosis lung disease.

Authors:  R C Boucher
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 2.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 3.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

4.  Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors.

Authors:  Anne Keriel; Céline René; Chad Galer; Joseph Zabner; Eric J Kremer
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Authors:  A M Krieg; T Wu; R Weeratna; S M Efler; L Love-Homan; L Yang; A K Yi; D Short; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

6.  Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins.

Authors:  R P Wersto; E R Rosenthal; P K Seth; N T Eissa; R E Donahue
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 7.  Strategies for correcting the delta F508 CFTR protein-folding defect.

Authors:  C R Brown; L Q Hong-Brown; W J Welch
Journal:  J Bioenerg Biomembr       Date:  1997-10       Impact factor: 2.945

8.  Inhibition of bovine endothelial cell activation in vitro by regulated expression of a transdominant inhibitor of NF-kappa B.

Authors:  J Anrather; V Csizmadia; C Brostjan; M P Soares; F H Bach; H Winkler
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

9.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.

Authors:  Linh Pham; Takafumi Nakamura; A Gabriela Rosales; Stephanie K Carlson; Kent R Bailey; Kah-Whye Peng; Stephen J Russell
Journal:  J Gene Med       Date:  2009-03       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.